Yasmeen Abouelhassan (David P Nicolau)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 24

Top Topics

Pseudomonas Aeruginosa

Antimicrobial Resistance

Acute Respiratory Distress Syndrome

Top Venues

The Journal of antimicrobial chemotherapy

JAC-antimicrobial resistance

Open forum infectious diseases

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

This page only lists publications with an associated author ORCID identifier.

Publications

Andrew J Fratoni, Matthew L Gethers, Yasmeen Abouelhassan, Joseph L Kuti
Non-KPC Attributes of Newer β-lactamase/β-lactamase Inhibitors, Part 1: Enterobacterales and Pseudomonas aeruginosa. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)
Tomefa E Asempa, Yasmeen Abouelhassan
Comment on: Comparison of carbapenem MIC for NDM-producing Enterobacterales by different AST methods: considerations for media composition. JAC-antimicrobial resistance 6 (3) (2024)
Yasmeen Abouelhassan, David P Nicolau, Kamilia Abdelraouf
Defining optimal sulbactam regimens for treatment of Acinetobacter baumannii pneumonia and impact of blaOXA-23 on efficacy. The Journal of antimicrobial chemotherapy 79 (9) (2024)
Tomefa E Asempa, Yasmeen Abouelhassan
Comment on: Comparison of carbapenem MIC for NDM-producing Enterobacterales by different AST methods: considerations for media composition. JAC-antimicrobial resistance 6 (3) (2024)
Tomefa E Asempa, Yasmeen Abouelhassan
Comment on: Comparison of carbapenem MIC for NDM-producing Enterobacterales by different AST methods: considerations for media composition. JAC-antimicrobial resistance 6 (3) (2024)
Aliaa Fouad, Samantha E Nicolau, Pranita D Tamma, Patricia J Simner, Yasmeen Abouelhassan, Christian M Gill
Assessing the impact of meropenem exposure on ceftolozane/tazobactam-resistance development in Pseudomonas aeruginosa using in vitro serial passage. The Journal of antimicrobial chemotherapy (2024)
Yasmeen Abouelhassan, David P Nicolau, Kamilia Abdelraouf
Defining optimal sulbactam regimens for treatment of Acinetobacter baumannii pneumonia and impact of blaOXA-23 on efficacy. The Journal of antimicrobial chemotherapy (2024)
Tomefa E Asempa, Yasmeen Abouelhassan
Comment on: Comparison of carbapenem MIC for NDM-producing Enterobacterales by different AST methods: considerations for media composition. JAC-antimicrobial resistance 6 (3) (2024)
Victor H Ruiz, Christian M Gill, Yasmeen Abouelhassan
Assessing the in vivo impact of novel β-lactamase inhibitors on the efficacy of their partner β-lactams against serine carbapenemase-producing Pseudomonas aeruginosa using human-simulated exposures. The Journal of antimicrobial chemotherapy (2024)
Aliaa Fouad, Yasmeen Abouelhassan, Christian M Gill
In vitro synergy of the combination of sulbactam-durlobactam and cefepime at clinically relevant concentrations against A. baumannii, P. aeruginosa and Enterobacterales. The Journal of antimicrobial chemotherapy (2023)
Tomefa E Asempa, Joseph L Kuti, Jeffrey C Nascimento, Samuel J Pope, Edward L Salerno, Patrick J Troy, Yasmeen Abouelhassan
Bronchopulmonary disposition of IV cefepime/taniborbactam (2-0.5 g) administered over 2 h in healthy adult subjects. The Journal of antimicrobial chemotherapy 78 (3) (2023)
Yasmeen Abouelhassan, Christian M Gill, David P Nicolau
Assessing the in vivo efficacy of rational antibiotics and combinations against difficult-to-treat Pseudomonas aeruginosa producing GES β-lactamases. The Journal of antimicrobial chemotherapy (2023)
Kamilia Abdelraouf, Yasmeen Abouelhassan
In vivo pharmacokinetic/pharmacodynamic evaluation of cefepime/taniborbactam combination against cefepime-non-susceptible Enterobacterales and Pseudomonas aeruginosa in a murine pneumonia model. The Journal of antimicrobial chemotherapy 78 (3) (2023)
Tomefa E Asempa, Abigail K Kois, Christian M Gill, Yasmeen Abouelhassan
Phenotypes, genotypes and breakpoints: an assessment of β-lactam/β-lactamase inhibitor combinations against OXA-48. The Journal of antimicrobial chemotherapy 78 (3) (2023)
Tomefa E Asempa, Joseph L Kuti, Jeffrey C Nascimento, Samuel J Pope, Edward L Salerno, Patrick J Troy, Yasmeen Abouelhassan
Bronchopulmonary disposition of IV cefepime/taniborbactam (2-0.5 g) administered over 2 h in healthy adult subjects. The Journal of antimicrobial chemotherapy 78 (3) (2023)
Christian M Gill, Debora Santini, Miki Takemura, Christopher Longshaw, Yoshinori Yamano, Roger Echols, Yasmeen Abouelhassan
In vivo efficacy & resistance prevention of cefiderocol in combination with ceftazidime/avibactam, ampicillin/sulbactam or meropenem using human-simulated regimens versus Acinetobacter baumannii. The Journal of antimicrobial chemotherapy (2023)
Andrew J Fratoni, Angela V Berry, Xiao Liu, Xi Chen, Yuchuan Wu, Yasmeen Abouelhassan, Kamilia Abdelraouf
Imipenem/funobactam (formerly XNW4107) in vivo pharmacodynamics against serine carbapenemase-producing Gram-negative bacteria: a novel modelling approach for time-dependent killing. The Journal of antimicrobial chemotherapy 78 (9) (2023)
Kamilia Abdelraouf, Yasmeen Abouelhassan
In vivo pharmacokinetic/pharmacodynamic evaluation of cefepime/taniborbactam combination against cefepime-non-susceptible Enterobacterales and Pseudomonas aeruginosa in a murine pneumonia model. The Journal of antimicrobial chemotherapy 78 (3) (2023)
Aliaa Fouad, Christian M Gill, Patricia J Simner, Yasmeen Abouelhassan, Tomefa E Asempa
Cefepime in vivo activity against carbapenem-resistant Enterobacterales that test as cefepime susceptible or susceptible-dose dependent in vitro: implications for clinical microbiology laboratory and clinicians. The Journal of antimicrobial chemotherapy (2023)
Maxwell J Lasko, Jennifer L Tabor-Rennie, Yasmeen Abouelhassan, Joseph L Kuti
Trimethoprim/sulfamethoxazole pharmacodynamics against Stenotrophomonas maltophilia in the in vitro chemostat model. The Journal of antimicrobial chemotherapy 77 (11) (2022)
Andrew J Fratoni, Lindsay M Avery, Yasmeen Abouelhassan, Tomefa E Asempa
In vivo pharmacokinetics and pharmacodynamics of ceftibuten/ledaborbactam, a novel oral β-lactam/β-lactamase inhibitor combination. The Journal of antimicrobial chemotherapy (2022)
Andrew J Fratoni, Abigail K Kois, Jessica L Colmerauer, Kristin E Linder, Yasmeen Abouelhassan, Joseph L Kuti
Impact of a Pharmacist-Managed Procalcitonin Program on COVID-19 Respiratory Tract Infection Outcomes and Health Care Resource Utilization. Open forum infectious diseases 9 (9) (2022)
Yasmeen Abouelhassan, Andrew J Fratoni, Ashley K Shepard, David P Nicolau, Tomefa E Asempa
Pharmacokinetics and soft-tissue distribution of tebipenem pivoxil hydrobromide using microdialysis: a study in healthy subjects and patients with diabetic foot infections. The Journal of antimicrobial chemotherapy (2022)
Aliaa Fouad, Richard Quintiliani, Yasmeen Abouelhassan, Tomefa E Asempa
Relative bioavailability of crushed tebipenem administered through a nasogastric tube with and without enteral feeding. The Journal of antimicrobial chemotherapy (2022)